CD274 and non-small cell lung carcinoma: The UNITO-001 (NCT04940637) is another prospective, single-arm, phase-2 trial investigating the safety and efficacy of combination niraparib and dostarlimab in patients with advanced NSCLC and malignant pleural mesothelioma with germline or somatic mutations in HR genes and positive PD-L1 expression (TPS ≥ 1%).